Thoraflex Hybrid and Relay Extension Post-Approval Study
Launched by VASCUTEK LTD. · Dec 5, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Thoraflex Hybrid and Relay Extension Post-Approval Study is looking at how effective a medical device called the Thoraflex Hybrid is in treating certain serious conditions that affect the aorta, which is the main artery in the body. This study will also explore how well the Thoraflex Hybrid works when used together with another device called the RelayPro NBS stent-graft. Patients who are 18 years or older and are being treated with the Thoraflex Hybrid device, with the possibility of additional treatment using the RelayPro device, may be eligible to join the study.
If you participate, you can expect to have your treatment monitored over a period of 10 years, following standard medical care at the hospital where you receive treatment. To join, you need to give your consent and be able to attend regular check-ups. However, if you have certain medical or psychological conditions that may affect your ability to participate safely, you may not qualify for the study. This research aims to gather important information to help improve treatments for aortic diseases, benefiting future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is aged 18 years or older on date of consent. Patient is willing and able to comply with all study procedures and visits. Patient or their next of kin (NOK)/legally designated representative (LDR) has given written informed consent to participate in the study.
- • Patient will undergo treatment with a Thoraflex Hybrid device. If a patient requires an extension procedure due to the extent of aortic disease, a RelayPro NBS Stent-graft should be placed inside the distal end of the previously placed Thoraflex Hybrid device via a retrograde approach. This may be part of the same or a two-stage procedure.
- Exclusion Criteria:
- • Patient has any medical, social, or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure.
About Vascutek Ltd.
Vascutek Ltd. is a leading medical device company specializing in the development and manufacturing of innovative vascular grafts and associated technologies. With a commitment to advancing patient care, Vascutek is dedicated to providing high-quality, reliable solutions for the treatment of vascular diseases. The company's extensive expertise in biomaterials and surgical techniques underpins its clinical trials aimed at evaluating the safety and efficacy of its products. Vascutek's mission is to enhance surgical outcomes and improve the quality of life for patients worldwide through rigorous research, collaboration, and adherence to the highest standards of regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Boston, Massachusetts, United States
Philadelphia, Pennsylvania, United States
Baltimore, Maryland, United States
Salt Lake City, Utah, United States
St. Louis, Missouri, United States
Aurora, Colorado, United States
Saint Louis, Missouri, United States
Hartford, Connecticut, United States
Durham, North Carolina, United States
Barcelona, , Spain
Pittsburgh, Pennsylvania, United States
Salzburg, , Austria
Freiburg, , Germany
New York, New York, United States
New York, New York, United States
Toulouse, , France
Saint Herblain, , France
Los Angeles, California, United States
Los Angeles, California, United States
Washington, District Of Columbia, United States
Houston, Texas, United States
Birmingham, Alabama, United States
Indianapolis, Indiana, United States
Austin, Texas, United States
Bologna, , Italy
Oxford, , United Kingdom
Patients applied
Trial Officials
Martin Czerny
Principal Investigator
University of Freiburg
Joseph E Bavaria
Principal Investigator
Jefferson Health and Sidney Kimmel Medical College
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials